9 Geographic Atrophy Clinical Trials in Tucson, AZ (2026)

Q: How do I join a clinical trial in Tucson?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you.

Recruiting Geographic Atrophy Studies in Tucson

NCT00358943Recruiting

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatme...

Tucson, AZ12,000 participantsGenzyme, a Sanofi Company

View Study Details

NCT05208047Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients. Part 1 consists of two...

Tucson, AZPHASE3482 participantsCogent Biosciences, Inc.

View Study Details

NCT06230185Recruiting

CtDNA Based MRD Testing for NAC Monitoring in TNBC

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR...

Tucson, AZ422 participantsPersonalis Inc.

View Study Details

NCT07220915Recruiting

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infection in Patients with Hypogammaglobulinemia and Aut...

Tucson, AZPHASE3360 participantsOctapharma

View Study Details

NCT07260916Recruiting

Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation

MINUTE is a prospective, multi-center, randomized, controlled, blinded assessor, adaptive enrichment design, clinical trial. Eligible patients with spontaneous BGH ≥20 mL will be randomized 1:1 to eit...

Tucson, AZNA300 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT06724237Recruiting

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete...

Tucson, AZPHASE3294 participantsEastern Cooperative Oncology Group

View Study Details

NCT06445972Recruiting

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, ...

Tucson, AZPHASE1210 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06469944Recruiting

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of sacituzumab tirumotecan with pembrolizumab and fluoropyrimidine chemotherapy for ...

Tucson, AZPHASE1160 participantsMerck Sharp & Dohme LLC

View Study Details

NCT04660760Recruiting

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction canc...

Tucson, AZPHASE2116 participantsAcademic and Community Cancer Research United

View Study Details

About Geographic Atrophy Clinical Trials in Tucson

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 9 geographic atrophy clinical trials recruiting participants in Tucson, AZ. These studies are seeking a combined 14,344 participants. Research is being sponsored by Genzyme, a Sanofi Company, Cogent Biosciences, Inc., Personalis Inc. and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in Tucson — FAQ

Are there geographic atrophy clinical trials in Tucson?

Yes, there are 9 geographic atrophy clinical trials currently recruiting in Tucson, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tucson?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.

Are clinical trials in Tucson free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 9 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated October 15, 2026 from ClinicalTrials.gov